Evidence map›Paper›PMID 19789337›Full record

ArticleCancer research2009

Haplotype and cell proliferation analyses of candidate lung cancer susceptibility genes on chromosome 15q24-25.1.

Yan Liu, Pengyuan Liu, Weidong Wen, Michael A James, Yian Wang, Joan E Bailey-Wilson, Christopher I Amos, Susan M Pinney, Ping Yang, Mariza de Andrade and 14 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. A Decade of GWAS Results in Lung Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 1 country.

Yan LiuWashington University, St. Louis, Missouri, USA.
Pengyuan Liu
Weidong Wen
Michael A James
Yian Wang
Joan E Bailey-Wilson
Christopher I Amos
Susan M Pinney
Ping Yang
Mariza de Andrade
Gloria M Petersen
Jonathan S Wiest
Pamela R Fain
Ann G Schwartz
Adi Gazdar
Colette Gaba
Henry Rothschild
Diptasri Mandal
Elena Kupert
Juwon Lee
Daniela Seminara
John Minna
Marshall W Anderson
Ming You
Washington University in St. Louis · USUniversity of Cincinnati · USMayo Clinic · USLouisiana State University Health Sciences Center New Orleans · USNational Institutes of Health · USThe University of Texas Southwestern Medical Center · USNational Human Genome Research Institute · USThe University of Texas MD Anderson Cancer Center · USUniversity of Colorado Denver · USUniversity of Toledo · USWayne State University · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY RESEARCHP30ES006096 · NIEHS · UNIVERSITY OF CINCINNATI · PI YADAV, JAGJIT S · 1992 to 2022
$35.4M
Genetic Epidemiology of CancerZIAHG200331 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BAILEY-WILSON, JOAN ELLEN · 2009 to 2022
$11.7M
GENETIC EPIDEMIOLOGY OF LUNG CANCERU01CA076293 · NCI · UNIVERSITY OF CINCINNATI · PI ANDERSON, MARSHALL W · 1999 to 2009
$11.5M
ALPHA 1 AD CARRIERS AND LUNG CANCER RISKR01CA080127 · NCI · MAYO CLINIC ROCHESTER · PI YANG, PING · 2000 to 2009
$4.4M
MOLECULAR GENETICS OF MOUSE LUNG TUMORSR01CA058554 · NCI · WASHINGTON UNIVERSITY · PI YOU, MING · 1998 to 2009
$2.3M
Identification of Pulmonary Lung Tumor Resistance 1 QTL CandidatesR01ES013340 · NIEHS · WASHINGTON UNIVERSITY · PI YOU, MING · 2004 to 2008
$1.8M
Positioning Cloning of Lung Cancer Modifier Gene Par2R01CA099147 · NCI · WASHINGTON UNIVERSITY · PI YOU, MING · 2003 to 2007
$1.7M
MECHANISM OF MOUSE LUNG CARCINOGENESISR01CA093643 · NCI · WASHINGTON UNIVERSITY · PI YOU, MING · 2002 to 2006
$1.6M
Genetic Basis of Lung Tumor Progression in MiceR01CA099187 · NCI · WASHINGTON UNIVERSITY · PI YOU, MING · 2003 to 2006
$1.2M
Positional Cloning of the Pas 1 QTL in miceR01ES012063 · NIEHS · WASHINGTON UNIVERSITY · PI YOU, MING · 2003 to 2006
$1.2M
Intramural NIH HHSNCI NIH HHS N01 PC035145NCI NIH HHS N01-PC35145NCI NIH HHS P30 CA022453NCI NIH HHS P30CA22453NCI NIH HHS P50 CA070907NCI NIH HHS P50CA70907NCI NIH HHS R01 CA058554NCI NIH HHS R01CA058554NCI NIH HHS R01 CA063700NCI NIH HHS R01 CA080127NCI NIH HHS R01 CA093643NCI NIH HHS R01CA093643NCI NIH HHS R01 CA099147NCI NIH HHS R01CA099147NCI NIH HHS R01 CA099187NCI NIH HHS R01CA099187NCI NIH HHS R01CA63700NCI NIH HHS R01CA80127NCI NIH HHS R03 CA077118NCI NIH HHS U01 CA076293NCI NIH HHS U01CA76293NHGRI NIH HHS N01 HG065404NIEHS NIH HHS P30 ES006096NIEHS NIH HHS P30ES06096NIEHS NIH HHS R01 ES012063NIEHS NIH HHS R01ES012063NIEHS NIH HHS R01 ES013340NIEHS NIH HHS R01ES013340
6 · The paper itself

Abstract

Recent genome-wide association studies have linked the chromosome 15q24-25.1 locus to nicotine addiction and lung cancer susceptibility. To refine the 15q24-25.1 locus, we performed a haplotype-based association analysis of 194 familial lung cases and 219 cancer-free controls from the Genetic Epidemiology of Lung Cancer Consortium (GELCC) collection, and used proliferation and apoptosis analyses to determine which gene(s) in the 15q24-25.1 locus mediates effects on lung cancer cell growth in vitro. We identified two distinct subregions, hapL (P = 3.20 x 10(-6)) and hapN (P = 1.51 x 10(-6)), which were significantly associated with familial lung cancer. hapL encompasses IREB2, LOC123688, and PSMA4, and hapN encompasses the three nicotinic acetylcholine receptor subunit genes CHRNA5, CHRNA3, and CHRNB4. Examination of the genes around hapL revealed that PSMA4 plays a role in promoting cancer cell proliferation. PSMA4 mRNA levels were increased in lung tumors compared with normal lung tissues. Down-regulation of PSMA4 expression decreased proteasome activity and induced apoptosis. Proteasome dysfunction leads to many diseases including cancer, and drugs that inhibit proteasome activity show promise as a form of cancer treatment. Genes around hapN were also investigated, but did not show any direct effect on lung cancer cell proliferation. We concluded that PSMA4 is a strong candidate mediator of lung cancer cell growth, and may directly affect lung cancer susceptibility through its modulation of cell proliferation and apoptosis.

Indexed as

Chromosomes, Human, Pair 15Carcinoma, Non-Small-Cell LungCell Growth ProcessesCell Line, TumorGenetic Predisposition to DiseaseHaplotypesHumansLung NeoplasmsPhysical Chromosome MappingProteasome Endopeptidase ComplexProteasome Endopeptidase Complex

Identifiers

PMID19789337
PMCPMC2846106
OpenAlexW1967451092

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.